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Abstract
Purpose The aim of this study was to compare the esophageal
findings of 2-deoxy-2-[18F]fluoro-D-glucose positron emis-
sion tomography–computed tomography (18F-FDG PET/CT)
and esophagogastroduodenoscopy (EGD).
Methods We retrospectively reviewed 18F-FDG PET/CT and
EGD findings of 369 subjects who underwent medical exam-
ination between January 2014 and December 2014. The range
and intensity of esophageal 18F-FDG uptake were visually
analyzed. The maximum standardized uptake value (SUVmax)
of the esophagus and around the esophagogastric (EG) junc-
tion was measured. EGD results were provided by the gastro-
enterologist. We compared the esophageal findings obtained
using 18F-FDG PET/CT and EGD.
Results There were typical linear FDG uptakes in 18F-FDG
PET/CT patients who underwent EGD the same day. In visual
analysis of the range and intensity of the 18F-FDG uptake, the
patients who underwent 18F-FDG PET/CT and EGD on the
same day showed relatively diffuse and discernible 18F-FDG
uptake in the esophagus. Reflux esophagitis was diagnosed in
59 subjects, and 27 of these were classified as higher than Los
Angeles classification A. With an increasing degree of reflux
esophagitis observed on EGD, the SUVmax in the esophagus
and around the EG junction was also increased.
Conclusion Our study showed that FDG uptake at the esoph-
agus or the EG junction might be clinically significantly relat-
ed to esophagitis. However, EGD performed before 18F-FDG
PET/CT on the same day may affect the esophageal 18F-FDG
uptake.
Keywords Positron emission tomography .
Esophagogastroduodenoscopy . Esophagus . Reflux
esophagitis . Physiologic activity
Introduction
Positron emission tomography (PET) with 2-deoxy-
2-[18F]fluoro-D-glucose ([18F]FDG) is a useful modality in
the diagnosis of various medical conditions and is being in-
creasingly used worldwide. 18F-FDG, a radionuclide glucose
analog, accumulates in the cells with glycolytic activity.
Therefore, FDG PET is a sensitive tool for detecting various
malignancies; however, cellular FDG uptake is not limited to
the malignant process alone [1–5]. There are a number of
benign conditions, including physiologic uptake and normal
variants of many organs, or inflammatory processes, in which
cells show 18F-FDG uptake. Thus, for a more accurate inter-
pretation of the 18F-FDG PET/CT findings, it is important to
know about the benign conditions in which 18F-FDG uptake
increases. Thus far, although there have been many studies on
physiologic 18F-FDG uptake and 18F-FDG uptake in benign
diseases [6–10], some physiologic or inflammatory findings
are not well understood.
Physiologic 18F-FDG uptake and 18F-FDG uptake in be-
nign disease of the stomach are well described because the
diseases of the stomach are relatively common and diverse
[11]; however, few studies have evaluated 18F-FDG uptake
in the esophagus [12, 13]. The prevalence of gastroesophageal
reflux disease (GERD) is very high worldwide [14, 15] and
has increased rapidly during recent years in Korea [16].
GERD has a variety of clinical manifestations, and sometimes
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the symptoms can be severe. In addition, previous studies
have reported that reflux esophagitis increases the risk of
esophageal adenocarcinoma [17–20]. However, despite the
high prevalence and importance of GERD and reflux esopha-
gitis, only few studies have assessed the correlation between
reflux esophagitis and 18F-FDG uptake so far [21].
The purpose of this study was to compare the findings of
esophageal 18F-FDGPET/CTand esophagogastroduodenoscopy
(EGD), with the focus on reflux esophagitis. We also ana-




We retrospectively enrolled 369 subjects who underwent 18F-
FDG PET/CTand EGD between January 2014 and December
2014. Subject history was recorded for proper interpretation of
the 18F-FDG PET/CT data. Subjects who had undergone
esophagus or stomach surgery as well as those with poor reg-
istration on 18F-FDG PET/CT were excluded. Most of the
subjects underwent 18F-FDG PET/CT and EGD on the same
day per the protocols defined at our health check-up center.
EGD was performed first, followed by 18F-FDG PET/CT
scanning. For subjects who underwent 18F-FDG PET/CT
and EGD on different days, if the time between the two pro-
cedures was >1 month, the subjects were excluded.
18F-FDG PET/CT
18F-FDG PET/CT scans were performed using a PET/CT
scanner (Biograph mCT 20 Excel, Siemens). All patients were
fasted for at least 6 h, and the peripheral blood glucose level
was confirmed to be ≤140 mg/dl before FDG injection. 18F-
FDG was intravenously administered at 5.5 MBq/kg of body
weight. PET/CTscanning from the skull base to the mid-thigh
was performed 60 min after intravenous injection of FDG.
After the initial low-dose CT study, a standard PET protocol
was used for scanning, with an acquisition time of 2 min per
bed position. The acquired images were reconstructed using
the iterative True X + TOF algorithm.
Image Analysis
18F-FDG PET/CT images were interpreted on interactive
workstations by two board-certified nuclear medicine physi-
cians, and any equivocal cases were resolved by consensus.
Readers were blinded to the results of EGD at the time of the
PET image review. Image interpretation was based on visual
and semiquantitative analysis using the attenuation-corrected
PET emission images. The intensity of the focal 18F-FDG
uptake was expressed as the maximum standardized uptake
value (SUVmax).
The range and intensity of esophageal involvement were
visually analyzed. Visual grading of the ranges was divided
into grade 0 to 3 (0=no discernible or focal uptake; 1=less
than one-third of the esophagus; 2=more than one-third of the
esophagus; 3=nearly or entire esophagus). The intensity of
the esophageal uptake was also visually analyzed and divided
into grade 0 to 3 (0=no discernible uptake; 1=minimal up-
take; 2=similar to liver uptake; 3=higher than liver uptake).
The SUVmax values of the esophagus and around the
esophagogastric (EG) junction were measured, and the specif-
ic locations were recorded. If ambiguous, the board-certified
radiologist confirmed the location of the EG junction. Some
cases with poor registration were excluded after this step.
EGD Analysis
EGD results were provided by the gastroenterologist. All sub-
jects were fasted from 9 p.m. the previous day until the endo-
scopic procedures had been performed by experienced
endoscopists. Reflux esophagitis was diagnosed and graded
according to the Los Angeles classification. Hiatus hernia and
other minor findings, including Barrett’s esophagus, were also
recorded.
Statistical Analysis
Differences in variables between subject groups were ana-
lyzed using the Mann-Whitney and Student t-test as well as
one-way ANOVA test. Optimal cutoff values for continuous
variables were determined using receiver-operating character-
istic (ROC) curve analysis. Statistical analyses were per-
formed using SPSS version 20.0 for Windows (SPSS Inc.),
and p<0.05 was considered statistically significant.
Results
Subject Characteristics
Of a total of 369 subjects, 33 with advanced cancer status,
history of gastrectomy or esophagectomy, or poor registration
on 18F-FDG PET/CT and 16 with a >1-month interval be-
tween 18F-FDG PET/CT and EGD were excluded. Ten sub-
jects with minor findings on EGD were also excluded. Of the
remaining 310 subjects, 262 had undergone 18F-FDGPET/CT
and EGD on the same day. According to the health check-up
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protocol followed at our check-up center, EGDwas performed
first, followed by 18F-FDG PET/CT (Fig. 1).
EGD Findings
Reflux esophagitis was diagnosed in 59 (19.03 %) subjects,
with 27 (8.71 %) of them classified as having higher than Los
Angeles classification A. Hiatus hernia was diagnosed in 15
(4.84 %) subjects on EGD; other minor findings included
esophageal polyp, esophageal diverticulum, glycogenic
acanthosis, heterotopic gastric mucosa, Barrett’s esophagus,
Mallory-Weiss tear, and esophageal submucosal tumor.
Correlation Between Prior EGD and Esophageal Uptake
in 18F-FDG PET/CT
In several subjects who underwent 18F-FDG PET/CT and
EGD on the same day, typical linear FDG uptake was ob-
served (Fig. 2), and visual analysis of the range and intensity
of the 18F-FDG uptake showed relatively diffuse and discern-
ible 18F-FDG uptake in the whole esophagus (Table 1). How-
ever, there were no significant statistical differences in the
SUV values (Table 2).
Correlation Between SUVand Esophagitis Severity
by the Los Angeles Classification
As the degree of reflux esophagitis observed on EGD in-
creased, a greater value of the SUVmax in the esophagus and
around the EG junction was observed (Figs. 3, 4 and
Table 2). Figure 4 and Table 2 show the statistical sig-
nificance of SUV parameters according to the severity of
esophagitis.
ROC curve analysis was performed to determine the opti-
mal cutoff in cases of reflux esophagitis classified as greater
than Los Angeles classification A. When the cutoff for the
Fig. 1 Flowchart of inclusion
and exclusion of the study
population
Fig. 2 Typical findings of subjects who underwent PET-CTand EGD on
the same day; typical linear FDG uptake was observed in subjects who
underwent 18F-FDG PET/CT and EGD on the same day
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SUVEG junction was set at 2.99, the sensitivity and specificity
for the detection of esophagitis were 81.5 and 78.8 %, respec-
tively, and when the cutoff for SUVmax was set at 3.32, they
were 81.5 and 83.4 %, respectively (Fig. 5 and Table 3).
Other EGD Findings Affecting Esophageal Uptake
on 18F-FDG PET/CT
Fifteen (4.84 %) subjects were diagnosed with hiatus hernia
(SUVmax, 3.67±1.41; SUVEG junction, 3.27±1.02), and 8 of
these had reflux esophagitis. Only two subjects were diag-
nosed with Barrett’s esophagus (SUVmax, 3.28±0.48; SUVEG
junction, 3.53±0.86).
Discussion
The prevalence of GERD in Korea has been rapidly in-
creasing in recent years and has been reported as 3.4–
7.9 % [22]. The prevalence of reflux esophagitis in our
study was relatively higher than that reported previously;
one of the reasons could be that our study population
included subjects from Western countries, where the prev-
alence of GERD is relatively higher.
In several subjects who underwent 18F-FDG PET/CT
and EGD on the same day, visual analysis of the range
and intensity showed diffuse and discernible 18F-FDG
uptake in the esophagus. The influence of EGD, includ-
ing mechanical irritation by endoscopy, is suggested as
the main factor responsible for this diffuse 18F-FDG
uptake. However, there were no significant statistical
differences in SUV values between the subjects who
underwent 18F-FDG PET/CT and EGD on the same
day and on different days. It is supposed that the influ-
ence of EGD causing 18F-FDG uptake is not more pow-
erful than normal physiologic muscle uptakes. Owing to
its linear property of FDG uptake on the same day,
esophageal uptake by EGD was easily found on visual
analysis, but the intensity of FDG uptake was not
higher than focal physiologic uptake.
Early esophageal cancers, including superficial
esophageal squamous cell carcinoma, may show low-
grade FDG uptake. It is difficult to evaluate the T-
stage of early esophageal cancers on 18F-FDG PET/
CT [23, 24]. Sherard et al. showed that 18F-FDG
PET/CT is not indicated while staging superficial
Table 2 SUVanalysis by the Los Angeles classification
Degree of esophagitis
N=total number (%) (same day/different day)
Average SUVmax (range) p-value*
Total Same day Different day
No reflux
N=251 (81.0 %) (212/39) 2.74±0.62 (1.56–6.39) 2.74±0.60 2.72±0.69 0.822
Minimal
N=32 (10.3 %) (26/6) 3.02±0.98 (1.63–6.00) 3.00±1.02 3.16±0.80 0.720
LA class A
N=20 (6.5 %) (18/2) 3.85±0.99 (2.33–6.16) 3.77±1.00 4.59±0.52 0.272
LA class B
N=5 (1.6 %) (4/1) 4.98±1.53 (3.55–7.56) 5.16±1.71 4.28 0.677
LA class C & D
N=2 (0.6 %) (2/0) 8.01±0.38 (7.63–8.39) 8.01±0.38 –
*Statistical difference between ‘same day’ and ‘different day’
Table 1 EGD effect of esophageal uptake on 18F-FDG PET/CT; range/
intensity (no reflux subjects on EGD)
Degree Same day (n=212) Different day (n=39) p-value
Range 0 138 (65.10 %) 35 (89.74 %) 0.002
1 33 (15.57 %) 2 (5.13 %)
2 27 (12.74 %) 2 (5.13 %)
3 14 (6.60 %) 0 (0.00 %)
Intensity 0 132 (62.26 %) 32 (82.05 %) 0.016
1 38 (17.92 %) 4 (10.26 %)
2 39 (18.40 %) 3 (7.69 %)
3 3 (1.42 %) 0 (0.00 %)
Range: 0=no discernible or focal uptake; 1=less than one-third of the
esophagus; 2=more than one-third of the esophagus; 3=nearly or entire
esophagus/intensity: 0=no discernible uptake; 1=minimal uptake; 2=
similar to liver uptake; 3=higher than liver uptake
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esophageal cancers [25]. Moreover, Johannes et al. re-
ported that focality and eccentricity in visual analysis
of 18F-FDG uptake could help differentiate early ma-
lignant esophageal lesions from benign ones [12]. This
research is focused on the pattern of 18F-FDG uptake
because the SUV parameters did not show satisfactory
results. Generally, in the 1-day protocol, EGD is per-
formed first, followed by 18F-FDG PET/CT for radia-
tion safety. However, according to our results, EGD
performed before 18F-FDG PET/CT on the same day
may mask the malignant lesions or misinterpret the
extent of malignancy. Compared to operation or biop-
sy, the effect of noninvasive procedures such as EGD
is ignored. However, to overcome this limitation,
performing EGD and 18F-FDG PET/CT on the same
day should be avoided.
As the degree of reflux esophagitis observed on EGD in-
creased, the SUVmax in the esophagus and around the EG
junction were also increased. Despite the overlap, these find-
ings were clearly observed. Moreover, the cutoff values for
SUV for detecting reflux esophagitis, derived from the ROC
analysis, showed acceptable results in the present study
(Table 3 and Fig. 5). The SUV parameters presented in previ-
ous studies suggested the possibility of FDG PET/CT to detect
GERD or esophagitis [26, 27], which was also observed in our
study. On the other hand, Barrett’s esophagus is a conse-
quence of gastroesophageal reflux disease. The risk of esoph-
ageal adenocarcinoma is greater in cases diagnosed with
esophagitis; most of this malignancy seems to be related to
Barrett’s esophagus [20]. In our study, few cases were diag-
nosed with Barrett’s esophagus and showed relatively high-
grade FDG uptake, but the degree of FDG uptake was lower
than that in cases of severe esophagitis. This can be explained
because Barrett’s esophagus is not always associated with the
active inflammatory process [28, 29].
GERD can be caused by hiatus hernia [30–32]. According
to Yeom et al., among patients with reflux esophagitis, hiatal
hernia was found in 31.5 % in Korea [33]. Eight of 15 cases
with hiatus hernia were diagnosed as having reflux esophagi-
tis in our study. The subjects with hiatus hernia showed rela-
tively high prevalence of reflux esophagitis, and the SUV
parameters were statistically significant.
Our study had several limitations. Our findings proposed
that subjects undergoing PET-CT and EGD on the same day
show more diffuse and discernible FDG uptake along the
esophagus on PET-CT. However, the most influential factor
causing these findings is not clear. The factors related to EGD,
such as inspection time, preconditioning, difficulty of the pro-
cedure, or skill of the gastroenterologist, may affect this up-
take, but these factors were not evaluated.Moreover, making a
Fig. 3 The correlation between SUV and esophagitis by the Los
Angeles classification. As the degree of reflux esophagitis observed on
EGD increased, a greater value of the SUVmax in the esophagus and
around the EG junction was observed. a Minimal reflux esophagitis
(SUVmax 2.42); b Los Angeles classification A (SUVmax 3.51), c
Los Angeles classification B (SUVmax 4.52), d Los Angeles
classification C (SUVmax 7.63), and e Los Angeles classification D
(SUVmax 8.39)
Nucl Med Mol Imaging (2016) 50:123–129 127
correlation between FDG uptake and symptoms of reflux
esophagitis was not possible in this study, because symptoms
such as heartburn or regurgitation were not recorded.
Some cases showed typical findings of severe reflux
esophagitis on 18F-FDG PET/CT, without notable find-
ings on EGD, possibly because of nonerosive reflux
disease (NERD) [34]; however, the exact cause of this
finding remains unclear. Another limitation of this study
is that it had a retrospective design. Although the total
number of subjects in this study was not small, not
enough cases had esophagitis graded as greater than
Los Angeles classification B, possibly because this
study was performed at a single institution in Korea, a
country with a relatively low prevalence of GERD.
It is not likely that PET-CT will be used as the diagnostic
modality for GERD, and EGD will remain the gold standard
for diagnosing diseases of the esophagus, including esophagi-
tis; however, our results will be helpful for interpreting esoph-
ageal uptake on 18F-FDG PET/CT.
Conclusion
Our study showed that FDG uptake at the esophagus or
at the EG junction might be related to clinically signif-
icant esophagitis. However, EGD performed shortly be-
fore 18F-FDG PET/CT on the same day may affect the
esophageal 18F-FDG uptake. If diffuse and discernible
18F-FDG uptake is observed at the esophagus on 18F-
FDG PET/CT, physicians should determine if the sub-




















Fig. 4 18F-FDG uptake and the
grades of esophagitis; the degree
of reflux esophagitis observed on
EGD was increased, and the
SUVmax in the esophagus and
around the EG junction was also
increased. It shows the statistical
significance in SUV parameters
according to the severity of
esophagitis
Fig. 5 Receiver-operator characteristic (ROC) curves of the SUVEG junc-
tion and SUVmax in differentiating esophagitis
Table 3 Diagnostic performance in the differentiation of no reflux and
minimal reflux from cases more severe than Los Angeles classification A
Parameter SUVEG junction SUVmax
Threshold >2.99 >3.32
Area under the curve 0.806 0.866
Sensitivity (%) 81.5 81.5
Specificity (%) 78.8 83.4
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